In 2013, the FDA placed a black boxed warning on the retigabine (ezogabine) drug label, related to risks of retinal abnormalities, potential vision loss, and blue discoloration of the skin, nail, mucous membrane, and eyes.
Retigabine was withdrawn in the UK from the beginning of 2017.
- TRADE NAMES: Potiga (GSK); Trobalt (GSK)
- INDICATIONS: Epilepsy
- SYNONYM: retigabine
- CLASS: Anticonvulsant (see also antiepileptic (anti-seizure)), Potassium channel opener
- HALF-LIFE: 7–11 hours
- FDA APPROVAL DATE: 06/10/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Carbamazepine, Digoxin, Phenytoin
- See adverse reactions attributed to class:
RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
